96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...

More documents

Recommendations

Info

SO-022 Specialized pathology review in patients with ovarian cancer: highly recommended to assure adequate treatment. Results from a prospective study S . Kommoss 1 , J . Pfisterer 2 , A . Reuss 3 , A . du Bois 4 , J . Diebold 5 , S . Hautmann 6 , D . Schmidt 7 , F . Kommoss 7 , for the AGO study group 8 1 University of British Columbia, Department of Pathology, Vancouver, Canada, 2 Klinikum Solingen, Dept of Gynecology, Solingen, 3 Philipps-Universität Marburg, Koordinierungszentrum für klinische Studien, Marburg, 4 Kliniken Essen Mitte (KEM), Dept Gynecology & Gyn .Oncology, 5 Luzerner Kantonsspital, Institute of Pathology, Luzern, Switzerland, 6 Institute of Pathology, Allgäu-Oberschwaben, Wangen i . A ., 7 Institute of Pathology, A 2 , 2 , Mannheim, 8 AGO study group, Wiesbaden Aims. In view of retrospective findings on second opinion pathology in ovarian cancer it seems certain, that a considerable number of ovarian borderline tumors (BOTs) or metastatic non-ovarian primaries are being erroneously diagnosed as ovarian carcinomas. If BOTs are misdiagnosed as cancer, patients may not only suffer from non-beneficial morbidity at unnecessary high cost but may have to cope with an incorrect diagnosis of cancer for the rest of their lives. In cases of metastatic disease mistaken for an ovarian primary, more adequate therapeutic modalities may be withheld from some patients. Finally, clinical trials may be biased through disregarding of histological inclusion criteria. We hypothesized that 5% of all patients in clinical trials of ovarian carcinomas have lesions other than epithelial ovarian cancer. This is the first such study with a prospective approach. Methods. Patients who were enrolled into a chemotherapy trial of ovarian carcinoma were asked to consent to a translational subprotocol. Contributing pathologists were asked to submit all original slides as well as paraffin material. Specialized central pathology review of all cases was performed by two experienced gynecopathologists. In cases of clinically relevant diagnostic discrepancies, the contributing pathologist was contacted. If a given discrepancy could not be resolved, a panel of experts was available for clarification. Results. 454 patients with an outside diagnosis of ovarian epithelial cancer were recruited. In 6.8% (n=31), a major diagnostic discrepancy of potential clinical relevance was found. Most frequently (n=15), serous BOTs had been misdiagnosed as invasive cancer. Ovarian metastases constituted the second most frequent misdiagnosis (n=12). As minor discrepancies, a divergent histological typing of ovarian carcinomas was found in 28.2% (n=128). Conclusions. This study clearly shows that central pathology review by experienced gynecopathologists is highly recommendable if overtreatment with chemotherapy of patients with BOTs and inadequate treatment of patients with ovarian metastases is to be avoided in the future. Specialized pathology review should become standard procedure in study protocols prior to randomization. In order to further optimize the quality of care, a high throughput infrastructure for specialized pathology review will have to be established. The authors propose a internetbased ovarian cancer network, capable of providing specialized second opinion pathology within 10 working days. SO-023 Development of a consortial database with pathological and clinical data for fresh frozen breast cancer specimen P . Bronsert1 , E . Stickeler2 , S . Schmid1 , K . Aumann1 , F . Haller3 , C . Röcken4 , N . Arnold5 , C . Mundhenke5 , F . Fend6 , A . Stäbler6 , T . Fehm7 , U . Vogel6 , M . Werner1 , O . Opitz8 1Albert-Ludwigs-University Freiburg, Institute of Pathology, Freiburg, 2Albert-Ludwigs-University Freiburg, Department of Obstetrics and Gynecology, Freiburg, 3Friedrich-Alexander-University Erlangen-Nürnberg, Institute of Pathology, Erlangen, 4Christian-Albrechts-University, Institute of Pathology, Kiel, 5Christian-Albrechts-University, Department of Gynecology and Obstetrics, Kiel, 6Eberhard Karls University Tübingen, Institute of Pathology, Tübingen, 7Eberhard Karls University Tübingen, Department of Gynecology and Obstetrics, Tübingen, 8Albert-Ludwigs-University Freiburg, Tumour Center Ludwig Heilmeyer, Freiburg Aims. Over the past two decades biomedical research technology in tumor banking has enabled significant advances in the molecular characterization of cancers, especially in research projects. Essential for the functioning of a high quality tumor bank is a standardized implementation of clinical and pathological information of tumor tissue. Each specific specimen cohort reflects certain quality characteristics of a tumor bank database and has to be handled in a certain manner. By combining three independent breast cancer biobanks with two different disciplines per facility together, it has to be assured, that each attendant is working with synchronized and harmonized standard operating procedures (SOP) and datasets. Methods. At all three attended facilities rules of internal procedure were defined, a Shared Resources Advisory was established, SOPs were partially new elaborated, harmonized and synchronized. Minimal obligate and facultative breast-cancer-specific, datasets for pathological and clinical diagnoses were established. A periodically updated, secured database with an automated combination of all consortial data was developed. A web page for public presentation and research access was designed. To attest effective consortial operation, tissue micro arrays (TMA) of a well specified, facility research related, patient cohort were established, sectioned and send to each facility where immunohistochemical staining was performed. The results will be published in a consortial publication. Results. From 2001 to 2011, the consortial breast cancer tissue bank contains 3400 fresh frozen, prospectively collected and immunohistochemically classified breast cancer samples from all three facilities. Nearly half of the patients were diagnosed with a ductal carcinoma in situ. The median age was 61 years. The common pT category was pT1c (n=1063), the most frequently pN category was pN0 (1693) followed by pN2 (n=197), pN1 (194) and pN3 (82). 1113 patients were ER and/or PR and/or HER2/ neu positive. After written request, access for researchers to the consortial internet accessible breast cancer database can be granted. Conclusions. A well planed clinicopathological, IT linked infrastructure is the fundament of a consortial database and the basic principle for multicentric translational research. Der Pathologe · Supplement 1 · 2012 | 67
Abstracts SO-024 Evaluation of tumor proliferation and hormone receptor status in breast cancer. Comparison of quantitative real time PCR, image analysis of IHC, and visual scoring H .-P . Sinn 1 , M . Keller 1 , N . Waldburger 2 , A . Schneeweiss 3 , R . Wirtz 4 1 University of Heidelberg, Institute for Pathology, Heidelberg, 2 University of Heidelberg, Dept . of Pathology, Heidelberg, 3 University of Heidelberg, National Center for Tumor Diseases, Heidelberg, 4 St . Elisabeth Krankenhaus, Dept . of Pathology, Köln Aims. The exact determination of hormone receptors, HER2 and proliferation is of outmost importance for clinical decision making in breast cancer. According to the 12th St Gallen Guidelines systemic therapy recommendations follow the subtypes classification originally defined by genetic array testing. These molecular subtypes can be approximated by clinicopathological parameters combining immunohistochemistry assessments of ER, PR, HER2 and Ki67. Methods. Matched fresh and fixed pretreatment biopsy samples were available from 90 patients participating in neoadjuvant clinical trial. RTqPCR data were available after extracting RNA using Qiagen kits. RNA was isolated from fixed tissue samples by using coated magnetic particles. Multiplex RT-qPCR was performed by TaqMan® based primer probe sets for ESR1, PGR, Ki67, as well as CALM2 as reference gene. Single Step RT-qPCR was performed by using Invitrogen reagents on a Stratagene MX3005p. RNA results were then reported as 40-CT values, which correlate proportionally to the mRNA expression level of the target gene. All cases were also used for quantitative immunohistology of nuclear antigens (ER, PR, Ki67) by automated image analysis on a virtual microscopy system (Aperio Technologies, Vista, CA, USA). Results. We observed a significant correlation of mRNA data from independent, matched fresh and fixed biopsy samples by using RT-qPCR (ER1 r=0,91; PR r=0,79, Ki67 r=0,72). When comparing automated image analysis results with conventional histological evaluation of IHC markers, there were only 3 cases misclassified for ER positivity or negativity, and 4 cases misclassified for PR positivity or negativity. Correlation of RT-qPCR data for ER and PR with quantitative immunohistology was highly significant (p
Page 2 and 3:
Inhalt Der Pathologe · Supplement
Page 4 and 5:
Inhalt Der Pathologe · Supplement
Page 6 and 7:
Editorial Liebe Kolleginnen und Kol
Page 8 and 9:
Kolorektales Karzinom 2 VO-005 Tran
Page 10 and 11:
Keynote Lecture VO-014 Genetic dete
Page 12 and 13:
(AMACR, FASN, GOLM1, GSP-pi, ERG) t
Page 14 and 15:
to assess the correct rate of R1 re
Page 16 and 17:
DNA damage, and cytotoxic drugs. Au
Page 18 and 19: HCV-positive formalin-fixed and par
Page 20 and 21: well as MET activation were examine
Page 22 and 23: or BRAF mutation, c-MYC and SIRT1 e
Page 24 and 25: AG Pneumopathologie III DO-032 Remo
Page 26 and 27: immature granulopoiesis showed a st
Page 28 and 29: ned, if well-defined mantle zones,
Page 30 and 31: phomas). Most prominent gains or am
Page 32 and 33: DO-062 Tumor-associated macrophages
Page 34 and 35: DO-080 DOG1: an immunohistochemical
Page 36 and 37: AG Oralpathologie DO-087 Detection
Page 38 and 39: DO-094 Do activated fibroblasts inf
Page 40 and 41: DO-101 Histopathological analysis o
Page 42 and 43: DO-108 Identification of potential
Page 44 and 45: Conclusions. In conclusion, 454 par
Page 46 and 47: subgroup of patients with B-Raf mut
Page 48 and 49: DO-002b Impact of terminologies in
Page 50 and 51: Methods. We performed MCPyV-FISH of
Page 52 and 53: FR-013 HPV-genotype distribution in
Page 54 and 55: Methods. Three different techniques
Page 56 and 57: (i.e. investment in equipment and e
Page 58 and 59: FR-032 COLD-PCR: a powerful tool in
Page 60 and 61: dissection (MBLND) technique to imp
Page 62 and 63: SO-005 Prevalence of mutations in s
Page 64 and 65: SO-011 Methylation profiling and in
Page 66 and 67: more effective than SAHA alone and
Page 70 and 71: SO-027 Ki-67 in mitotic score group
Page 72 and 73: nificantly associated with advanced
Page 74 and 75: liver did not correlate with the mu
Page 76 and 77: AG Paidopathologie II SO-046 Overex
Page 78 and 79: Results. Histomorphology of the ova
Page 80 and 81: p42 and p27 have not yet been inves
Page 82 and 83: SO-068 Recent advances in understan
Page 84 and 85: SO-075 A novel, dual role of CCN3 i
Page 86 and 87: Pancreatic Adenocarcinoma SG-137 Se
Page 88 and 89: sease and 30 colon cancer serum sam
Page 90 and 91: Conclusions. Although CRC is charac
Page 92 and 93: differentiated and TNM stage III or
Page 94 and 95: pressed moderate levels of the prot
Page 96 and 97: FR-P-037 MALDI imaging reveals COX7
Page 98 and 99: in the context of therapy response
Page 100 and 101: on primary cells of wild-type and c
Page 102 and 103: chemotherapy was recommended and co
Page 104 and 105: aims are twofold: 1) to verify the
Page 106 and 107: Results. Her2/neu status in TMAs an
Page 108 and 109: prognostic impact was found in rect
Page 110 and 111: provided information on survival ti
Page 112 and 113: Methods. Biopsy specimens from 430
Page 114 and 115: the OS rate was 53% for patients wi
Page 116 and 117: FR-P-098 Immunohistological stainin
Page 118 and 119:
FR-P-104 Histopathological evaluati
Page 120 and 121:
within the earliest morphologic det
Page 122 and 123:
Conclusions. In primary imaging a g
Page 124 and 125:
fibrotic neointma development as we
Page 126 and 127:
FR-P-129 Alpha-1-antitrypsin-PiZ-an
Page 128 and 129:
FR-P-136 The expression of central
Page 130 and 131:
cosa and in the periarterial tissue
Page 132 and 133:
FR-P-149 Combination of Castleman d
Page 134 and 135:
or without different concentrations
Page 136 and 137:
Results. In 18 cases (79%) the caus
Page 138 and 139:
FR-P-168 Autopsy findings in a 2-ye
Page 140 and 141:
FR-P-174 MPGN-like glomerulonephrit
Page 142 and 143:
Poster: Gynäkopathologie und Mamma
Page 144 and 145:
SA-P-011 Genetic aberrations of pre
Page 146 and 147:
Mechanismen, die eine Progression d
Page 148 and 149:
internet server. A network of inter
Page 150 and 151:
Methods. HE-gefärbte Schnittpräpa
Page 152 and 153:
Conclusions. The newly released 450
Page 154 and 155:
and desmoplastic reaction are diffe
Page 156 and 157:
one patient revealed more than 9 mi
Page 158 and 159:
situation, the V600E mutation in th
Page 160 and 161:
SA-P-064 Evolution of molecular pat
Page 162 and 163:
nic markers such as myf4 and MyoD1
Page 164 and 165:
Conclusions. To our knowledge, this
Page 166 and 167:
SA-P-085 Expression of the eukaryot
Page 168 and 169:
Results. The papillary RCC type II
Page 170 and 171:
SA-P-098 Male infertility: assessme
Page 172 and 173:
SA-P-104 Process oriented scientifi
Page 174 and 175:
Conclusions. The IBDW offers a uniq
Page 176 and 177:
L Lasitschka F. DO-046 Lehmann A. F
show all

96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...

Create successful ePaper yourself

Delete template?

Save as template?